Andrew Dudum, CEO of Hims & Hers, joined Leading Indicator to break down the company's latest earnings report, the rising demand for its compounded obesity drug, the recent $31 million acquisition of a compounding pharmacy, and the rapidly growing business for women's healthcare. Hosted by Hope King, Senior Business Reporter at Axios.

(Recorded August 6, 2024)

The content of the video is for general and informational purposes only. All views presented in this show reflect the opinions of the guest and the host. You should not take a mention of any asset, be it cryptocurrency or a publicly traded security as a recommendation to buy, sell or hold that cryptocurrency or security. Guests and hosts are not affiliated with or endorsed by Public Holdings or its subsidiaries. You should make your own financial and investment decisions or consult respective professionals. Full disclosures are in the channel description. Learn more at Public.com/disclosures. Past performance is not a guarantee of future results. There is a possibility of loss with any investment. Historical or hypothetical performance results, if mentioned, are presented for illustrative purposes only. Do not infer or assume that any securities, sectors or markets described in the videos were or will be profitable. Any statements of future expectations and other forward-looking statements are strictly based on the current views, opinion, or assumptions of the person presenting them, and should not be taken as an indicator of performance nor should be relied upon as an investment advice.

Hims & Hers CEO on Obesity Drug Safety and Expansion of its Women's Business